Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling

British Journal of Cancer

Volumn 110, Issue 6, 2014, Pages 1622-1633

  Atrih, A ^a   Mudaliar, M A V ^a,b   Zakikhani, P ^c   Lamont, D J ^a   Huang, J T J ^c   Bray, S E ^c   Barton, G ^a   Fleming, S ^c   Nabi, G ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Coronin 1A; kidney cancer; proteomics; urinary biomarkers

Indexed keywords

6 PHOSPHOFRUCTOKINASE; 6 PHOSPHOFRUCTOKINASE TYPE C; ADIPOPHILIN; AGGRECAN CORE PROTEIN; BETA INTEGRIN; CADHERIN; CADHERIN 16; CORONIN 1A; FAT DROPLET; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE B; LIPOCORTIN 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN TYROSINE KINASE; PROTEOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SERPIN H1; SIALIC ACID SYNTHASE; SYNAPTOPODIN; SYNAPTOPODIN 2; TAMM HORSFALL GLYCOPROTEIN; THYMIDINE PHOSPHORYLASE; TRANSCRIPTION FACTOR RUNX2; TRYPSIN; TUMOR MARKER; UBIQUITIN CARBOXYL TERMINAL HYDROLASE ISOZYME L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR; XYLULOSE REDUCTASE;

ADULT; AGED; AMINO ACID SYNTHESIS; ARTICLE; CANCER SURGERY; CANCER TISSUE; CITRIC ACID CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; FEMALE; FILTER AIDED SAMPLE PREPARATION; GENE OVEREXPRESSION; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; NEPHRECTOMY; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SOLUBILIZATION; TANDEM MASS SPECTROMETRY; TISSUE SECTION; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84896489030     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.24     Document Type: Article

References (67)

1. Balabanov S, Zimmermann U, Protzel C, Scharf C, Klebingat KJ, Walther R (2001) Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur J Biochem 268: 5977-5980.
2. Bijnsdorp IV, Capriotti F, Kruyt FA, Losekoot N, Fukushima M, Griffioen AW, Thijssen VL, Peters GJ (2011) Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. Br J Cancer 104: 1185-1192.
3. Bromwich EJ, McArdle PA, Canna K, McMillan DC, McNicol AM, Brown M, Aitchison M (2003) The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 89: 1906-1908.
4. Bronckaers A, Gago F, Balzarini J, Liekens S (2009) The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 29: 903-953.
5. Buhring HJ, Streble A, Valent P (2004) The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 133: 317-329.
6. Campbell SC, Flanigan RC, Clark JI. Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol (2003) 4: 363-372.
7. Chen EI, Yates 3rd JR (2007) Cancer proteomics by quantitative shotgun proteomics. Mol Oncol 1: 144-159.
8. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B (2001) PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7: 53-58.
9. D'Andrea FP, Safwat A, Kassem M, Gautier L, Overgaard J, Horsman MR (2011) Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance. Radiother Oncol 99: 373-378.
10. Drucker BJ (2005) Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 31: 536-545.
11. Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, Mulders P, Kataja V. ESMO Guidelines Working Group (2012) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7): vii65-vii71.
12. FLink: Frequency weighted links [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. 2010-[cited 2012/06/12]. Available from http://ncbi.nlm.nih.gov/Structure/flink/ flink.cgi.
13. Franchini M, Frattini F, Crestani S, Bonfati C, Lippi G (2013) Von Willebrand factor and cancer: a renewed interest. Thromb Res 131(4): 290-292.
14. Gaspare G, Porcelli A M, Lenaz G, Romeo G (2013) Relevance of mitochondrial genetics and metabolism in cancer development. Cold spring Harb Perspect Biol 5(2): 1-17.
15. Giribaldi G, Barbero G, Mandili G, Daniele L, Khadjavi A, Notarpietro A, Ulliers D, Prato M, Minero V G, Battaglia A, Allasia M, Bosio A, Sapino A, Gontero P, Frea B, Fontana D, Destefanis P (2013) Proteomic identification of reticulocalbin 1 as potential tumor marker in renal cell carcinoma. J Proteomics 91C: 385-392.
16. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34: 193-205.
17. Grebe SK, Erickson LA (2010) Screening for kidney cancer: is there a role for aquaporin-1 and adipophilin? Mayo Clin Proc 85(5): 410-412.
18. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
19. Hwa JS, Park HJ, Jung JH, Kam SC, Park HC, Kim CW, Kang KR, Hyun JS, Chung KH (2005) Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci 20: 450-455.
20. Jackson L, Wahli W, Michalik L, Watson SA, Morris T, Anderton K, Bell DR, Smith JA, Hawkey CJ, Bennett AJ (2003) Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer. Gut 52: 1317-1322.
21. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 30: 843-852.
22. Junker H, Venz S, Zimmermann U, Thiele A, Scharf C, Walther R (2011) Stage-related alterations in renal cell carcinoma-comprehensive quantitative analysis by 2D-DIGE and protein network analysis. PLoS One 6: e21867.
23. Kim DH, Bae J, Lee JW, Kim SY, Kim YH, Bae JY, Yi JK, Yu MH, Noh DY, Lee C (2009a) Proteomic analysis of breast cancer tissue reveals upregulation of actin-remodeling proteins and its relevance to cancer invasiveness. Proteomics Clin Appl 3: 30-40.
24. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS (2009b) Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 28: 20.
25. King SI, Purdie CA, Bray SE, Quinlan PR, Jordan LB, Thompson AM, Meek DW (2012) Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom. Breast Cancer Res 14: R40.
26. Klopfleisch R, Klose P, Weise C, Bondzio A, Multhaup G, Einspanier R, Gruber AD (2010) Proteome of metastatic canine mammary carcinomas: similarities to and differences from human breast cancer. J Proteome Res 9: 6380-6391.
27. Kowalczyk D, Skorupski W, Kwias Z, Nowak J (1997) Flow cytometric analysis of tumour-infiltrating lymophocytes in patients with renal cell carcinoma. Br J Urol 4: 543-547.
28. Lichtenfels R, Dressler SP, Zobawa M, Recktenwald CV, Ackermann A, Atkins D, Kersten M, Hesse A, Puttkammer M, Lottspeich F, Seliger B (2009) Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis. Mol Cell Proteomics 8: 2827-2842.
29. Masui O, White NM, DeSouza LV, Krakovska O, Matta A, Metias S, Khalil B, Romaschin AD, Honey RJ, Stewart R, Pace K, Bjarnason GA, Siu KW, Yousef GM (2013) Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics 12: 132-144.
30. Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29: 339-343.
31. Michalik L, Desvergne B, Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4: 61-70.
32. Modica-Napolitano JS, Kulawiec M, Singh KK (2007) Mitochondria and human cancer. Curr Mol Med 7: 121-131.
33. Morgan E, Kannan-Thulasiraman P, Noy N (2010) Involvement of fatty acid binding protein 5 and PPARbeta/delta in prostate cancer cell growth. PPAR Res 2010: 1-9.
34. Morrissey JJ, London AN, Luo J, Kharasch ED (2010) Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin Proc 85: 413-421.
35. Mugnier B, Nal B, Verthuy C, Boyer C, Lam D, Chasson L, Nieoullon V, Chazal G, Guo XJ, He HT, Rueff-Juy D, Alcover A, Ferrier P (2008) Coronin-1A links cytoskeleton dynamics to TCRab-induced cell signaling. PLoS One 3(10): e3467.
36. Najjar YG, Rini BI (2012) Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol 4: 183-194.
37. Okamura N, Masuda T, Gotoh A, Shirakawa T, Terao S, Kaneko N, Suganuma K, Watanabe M, Matsubara T, Seto R, Matsumoto J, Kawakami M, Yamamori M, Nakamura T, Yagami T, Sakaeda T, Fujisawa M, Nishimura O, Okumura K (2008) Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics 8: 3194-3203.
38. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kultz D, Weiss RH (2006) Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 5: 64.
39. Perroud B, Ishimaru T, Borowsky AD, Weiss RH (2009) Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteomics 8(5): 971-985.
40. Plate KH, Breier G, Millauer B, Ullrich A, Risau W (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53: 5822-5827.
41. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859-2867.
42. Rini BI, Atkins MB (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000.
43. Sarto C, Deon C, Doro G, Hochstrasser DF, Mocarelli P, Sanchez JC (2001) Contribution of proteomics to the molecular analysis of renal cell carcinoma with an emphasis on manganese superoxide dismutase. Proteomics 1: 1288-1294.
44. Schendel DJ, Gansbacher B (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Cancer Res 53: 4020-4025.
45. Schulze WX, Usadel B (2010) Quantitation in mass-spectrometry-based proteomics. Annu Rev Plant Biol 61: 491-516.
46. Seliger B, Lichtenfels R, Kellner R (2003) Detection of renal cell carcinoma-associated markers via proteome-and other 'ome'-based analyses. Brief Funct Genomic Proteomic 2: 194-212.
47. Shi T, Dong F, Liou LS, Duan ZH, Novick AC, DiDonato JA (2004) Differential protein profiling in renal-cell carcinoma. Mol Carcinog 40: 47-61.
48. Singer EA, Gupta GN, Marchalik D, Srinivasan R (2013) Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol 25(3): 273-280.
49. Tickoo SK, Gopalan A (2008) Pathologic features of renal cortical tumors. Urol Clin North Am 35: 551-561.
50. Tolle A, Suhail S, Jung M, Jung K, Stephan C (2011) Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma. BMC Cancer 11: 302.
51. Turcotte S, Desrosiers RR, Beliveau R (2004) Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Am J Physiol Renal Physiol 286: F338-F348.
52. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE (2003) Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 3: 1620-1632.
53. Urahama Y, Ohsaki Y, Fujita Y, Maruyama S, Yuzawa Y, Matsuo S, Fujimoto T (2008) Lipid droplet-associated proteins protect renal tubular cells from fatty acid-induced apoptosis. Am J Pathol 173: 1286-1294.
54. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930): 1029-1033.
55. Valera VA, Li-Ning-T E, Walter BA, Roberts DD, Linehan WM, Merino MG (2010) Protein expression profiling in the spectrum of renal cell carcinomas. Journal of Cancer 1: 184-196.
56. Veenstra TD (2007) Global and targeted quantitative proteomics for biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci 847: 3-11.
57. Walther TC, Mann M (2010) Mass spectrometry-based proteomics in cell biology. J Cell Biol 190: 491-500.
58. Wang M, You J, Bemis KG, Tegeler TJ, Brown DP (2008) Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Brief Funct Genomic Proteomic 7: 329-339.
59. Weiss RH, Lin PY (2006) Kidney cancer: identification of novel targets for therapy. Kidney Int 69: 224-232.
60. Wisniewski JR, Zougman A, Mann M (2009) Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J Proteome Res 8: 5674-5678.
61. Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY, Wei L (2011) KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res 39: W316-W322.
62. Yao M, Huang Y, Shioi K, Hattori K, Murakami T, Nakaigawa N, Kishida T, Nagashima Y, Kubota Y (2007) Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma. Clin Cancer Res 13: 152-160.
63. Yao M, Tabuchi H, Nagashima Y, Baba M, Nakaigawa N, Ishiguro H, Hamada K, Inayama Y, Kishida T, Hattori K, Yamada-Okabe H, Kubota Y (2005) Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol 205: 377-387.
64. Zanetta L, Marcus SG, Vasile J, Dobryansky M, Cohen H, Eng K, Shamamian P, Mignatti P (2000) Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int J Cancer 85: 281-288.
65. Zhao Y, Butler EB, Tan M (2013) Targeting cellular metabolism to improve cancer therapeutics. Cell Death Disease 4: e532.
66. Zhang J, Xie XY, Yang SW, Wang J, He C (2010) Nicotinamide N-methyltransferase protein expression in renal cell cancer. J Zhejiang Univ Sci B 11: 136-143.
67. Zhu W, Smith JW, Huang CM (2010) Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol 2010: 840518.